Neoadjuvant Radiation Lobectomy And Immunotherapy For Angioinvasive Hcc Resulting In Complete Pathologic Response

Radiation may augment the anti-tumoral immune response induced by immunotherapies, such as checkpoint inhibitors approved for treating advanced hepatocellular carcinoma (HCC) (1). We present two cases of HCC with vascular invasion successfully treated with ablative intent yttrium-90 (Y-90) radiation lobectomy (2) in conjunction with nivolumab as a neoadjuvant to resection and liver transplant resulting in complete pathologic response.